Insilico Medicine Launches PandaClaw – AI Agent Platform Transforms Biological Research with Natural Language Interface
Insilico Medicine (HKG: 3696) announced the launch of PandaClaw, a transformative new feature of its...
HKG: 3696
Insilico Medicine Partners with ASKA Pharma – AI‑Driven Target Discovery Collaboration Targets Gynecological Diseases
Insilico Medicine (HKG: 3696) announced a strategic drug discovery collaboration with ASKA Pharmaceutical Co., Ltd.,...
Insilico Medicine’s AI-Driven ISM4808 Hits Phase I Milestone – TaiGen Doses First Subject in CKD Anemia Trial
Insilico Medicine (HKG: 3696) announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease...
Insilico Medicine Launches AI‑Powered Automated Partnering System – Transforms Biotech Business Development
Insilico Medicine (HKG: 3696), a generative AI‑driven biotech, announced the pilot launch of its Automated Partnering...
Insilico Medicine Partners with MSKCC to Discover Gastroesophageal Cancer Targets – AI‑Driven Multi‑Omics Analysis
Insilico Medicine (HKG: 3696) announced a collaboration agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to...
Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone
Insilico Medicine (HKG: 3696) announced the first patient dosing in a Phase I clinical study...
Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal
Insilico Medicine (HKG: 3696), a generative AI‑driven biotech, announced a partnership with Shenzhen Hengtai Biotechnology...
Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease
Insilico Medicine (HKG: 3696) announced that the first patient has been dosed in the BETHESDA...
Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal
Insilico Medicine (HKG: 3696) announced a multi‑year R&D collaboration with Servier to identify and develop...
Insilico Medicine and Hisun Pharma Nominate PCC in 8 Months via AI Platform
Insilico Medicine (HKG: 3696) and Hisun Pharmaceutical (SHA: 600267) announced the nomination of a Preclinical...
InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B
InSilico Medicine Cayman TopCo (HKG: 3696) officially listed on the Hong Kong Stock Exchange, offering...